The Retina Radar With Dr. Arshad Khanani on CTS, nAMD, DME, and Sustained Delivery
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Activity Description
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like undertreatment and patient nonadherence. New and emerging therapies, particularly for conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), aim to reduce the burden of frequent injections through innovative mechanisms, such as gene therapy and sustained drug delivery systems. Recent advances include development of promising investigational treatments targeting various molecular pathways. In this CE activity, expert faculty review ongoing clinical trials; evaluate the latest data on the efficacy, safety, and management of nAMD and DME; and summarize the benefits and limitations of sustained delivery systems in the treatment of retinal diseases.
Target Audience
The intended audience for this activity is US-based ophthalmologists, retina specialists, optometrists, and other healthcare professionals involved in the management of retinal diseases.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review ongoing clinical trials and the latest data regarding advances in vitreoretinal care.
- Evaluate new efficacy, safety, and durability data on dosing regimens, delivery systems, and emerging therapies for the treatment of nAMD.
- Summarize the latest information, emerging clinical trial data, and real-world studies regarding the management of DME.
- Recognize the benefits and limitations of sustained delivery systems in the treatment of retinal diseases.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Professor of Surgery
University of Nevada, Reno School of Medicine
Reno, NV
Faculty
Peter A. Campochiaro, MD
Eccles Professor of Ophthalmology and Neuroscience
The Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD
David A. Eichenbaum, MD, FASRS
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
St. Petersburg, FL
Prof. Anat Loewenstein, MD
Professor & Director, Ophthalmology Division
Tel-Aviv Medical Center
Associate Dean of Medicine
Tel-Aviv University
Tel Aviv, Israel
Veeral Sheth, MD, MBA, FASRS
Director of Clinical Research
University Retina and Macula Associates
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
ACCREDITATION
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 31, 2024, to August 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Peter A. Campochiaro, MD
Royalties or Patent Beneficiary: Allegro
Advisor: Allegro, AsclepiX, Ashvattha, Exonate, Genentech/Roche, Perfuse
Consultant: Bausch + Lomb, Clearside, Exegenesis Bio, Janssen, Merck, Sanofi Genzyme
Independent Research Contractor: AbbVie, Genentech/Roche, Regenxbio, Sanofi
Stock Options: Allegro
David A. Eichenbaum, MD, FASRS
Consultant: Allergan, Annexon, Apellis, Astellas, Bausch + Lomb, Coherus, EyePoint, Genentech, Kodiak, Novartis, Ocular Therapeutix, Opthea, Outlook, Regeneron, Regenxbio, Samsara
Speaker Contracted by Ineligible Company: Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron
Independent Research Contractor: 4DMT, Aerie/Alcon, Alexion, Allgenesis, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, ONL, Regeneron, Regenxbio, Roche, Unity
Individual Stocks (publicly traded): Janssen
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis, Aviceda, Beacon Therapeutics, Clearside, Complement Therapeutics, Exegenesis, EyePoint, Fronterra, Genentech, Gyroscope, i-Lumen, Iveric Bio, Janssen, Kodiak, Kriya, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Unity Bio, Vanotech
Speaker Contracted by Ineligible Company: IVERIC bio
Independent Research Contractor: 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, EyePoint, Exegenesis, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Neurotech, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Regenxbio, Roche, Unity Bio, Vanotech
Stock Options: Aviceda, Oculis, Opthea, Perfuse, PolyPhotonix
*Individual Stocks (privately held): RevOpsis
Prof. Anat Loewenstein, MD
Consultant: Allergan, Bayer, Beyeonics, Iveric Bio, Johnson & Johnson Vision, Notal Vision, Novartis, Ripple, Roche, Syneos
Veeral Sheth, MD, MBA, FASRS
Consultant: Alimera, Apellis, EyePoint, Genentech, IVERIC bio, Kriya, Novartis, Regeneron, RevOpsis, Unity
Speaker Contracted by Ineligible Company: Alimera, Apellis, Genentech, IVERIC bio
Independent Research Contractor: 4DMT, AbbVie, Adverum, Alimera, Allergan, Ashvattha, Aviceda, Chengdu Kanghong, EyePoint, Genentech, Gyroscope, i-Lumen Scientific, Ionis, IVERIC bio, Janssen, NGM, Novartis, Ocular Therapeutix, Ocugen, OliX, Opthea, Outlook, Oxular, Oxurion, Perfuse, Regeneron, Regenxbio, Rezolute, Roche, SalutarisMD, Unity Bio, Vanotech
*Will not discuss business lines or products of company(ies).
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this podcast is available upon request. Requests should include the activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com